Cardiac Toxicity Clinical Trials

5 recruiting

Cardiac Toxicity Trials at a Glance

8 actively recruiting trials for cardiac toxicity are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Madrid, Amsterdam, and Barcelona. Lead sponsors running cardiac toxicity studies include Dr James Hare, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, and Dinesh Thavendiranathan.

Browse cardiac toxicity trials by phase

Treatments under study

About Cardiac Toxicity Clinical Trials

Looking for clinical trials for Cardiac Toxicity? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cardiac Toxicity trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cardiac Toxicity clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 4

The STOP-MED CTRCD Trial

Heart FailureCancerCardiotoxicity+2 more
Dinesh Thavendiranathan335 enrolled14 locationsNCT06183437
Recruiting
Phase 2

Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients

Breast CancerHeart FailureAnthracycline-induced Cardiac Toxicity+2 more
University Medical Centre Ljubljana100 enrolled1 locationNCT07245069
Recruiting
Phase 2

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

Cardiac Toxicity
Rutgers, The State University of New Jersey60 enrolled10 locationsNCT05559164
Recruiting
Not Applicable

REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs

Anthracycline-induced Cardiac ToxicityLymphoma
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III608 enrolled24 locationsNCT05223413
Recruiting
Phase 4

Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)

Breast CancerHeart FailureBreast Diseases+10 more
Silesian Centre for Heart Diseases600 enrolled4 locationsNCT05465031
Recruiting

Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies

CancerCardiac Toxicity
Fondazione Policlinico Universitario Agostino Gemelli IRCCS300 enrolled1 locationNCT06664528
Recruiting

COr Loco-regional Advanced Lung Cancer Treated With Chemo-radiotherapy (COLA)

Radiation ToxicityCardiac ToxicityLung Cancer Stage II+2 more
Odense University Hospital100 enrolled1 locationNCT05258448
Recruiting

Using cardiac magnetic resonance imaging to detect early changes in heart muscle that may help predict patients who are at risk of developing toxicity from anthracycline chemotherapy.

Anthracycline chemotherapy induced cardiac toxicityLymphoma
Dr James Hare50 enrolled1 locationACTRN12612001100886